摘要
目的观察国产长春瑞滨(NVB)联合顺铂(DDP)治疗晚期非小细胞肺癌(NSCLC)的疗效及不良反应。方法对入选的45例患者NVB25mg/m2,第1、8天静脉注入;DDP40mg,第1～3天静脉滴注,21d为1周期,至少4个周期。结果CR2例,PR18例,NC22例,PD3例,总有效率44.44%。毒副作用以恶心、呕吐、注射部位静脉反应及骨髓抑制等,占91.1%。结论国产长春瑞滨联合顺铂治疗晚期非小细胞癌有效率较高,毒副反应可以耐受,值得临床推广。
Objective To observe the clinical effect and side effects of NVB combined with cisplatine in the treatment of late non-small-cell lung cancer. Methods The selection of 45 cases of patients with NVB 25 mg/m^2 ,the first intravenous injection of 1,8 days; DDP 40 mg,1 to 3 days intravenous drip,for a period of 21 days, at least 4 cycles. Results Among the 45 cases, there were 2 cases of CR, 18 cases of PR,22 cases of NC and 3 cases of PD. The total effective rate was 44. 44%. Toxicity to nausea, vomiting, intravenous injection site reactions and bone marrow suppression and so on, accounting for 91.1%. Conclusion The clinical effective rate of NVB combined with cisplatine was high in the treatment of late non-small-cell lung cancer. And the side effects could be tolerated by the patients. So the treatment method was worth to be promoted in clinical.
出处
《中国现代药物应用》
2009年第12期16-17,共2页
Chinese Journal of Modern Drug Application
关键词
长春瑞滨
顺铂
化学治疗
非小细胞肺癌
Vinorelbine（NVB）
Cisplatine
Chemotherapy
Non-small-cell lung cancer
